Rep. Norm Thurston — Voting Record

Bill

Number

H.B. 500 (2025GS)

Sponsor

Rep. Dailey-Provost, Jennifer

Final action

House/ filed 3/7/2025

Outcome

Failed / filed without passage

Summary

What it does

• This bill:
• classifies amanita muscaria as a controlled substance.

Every vote on this bill

Bill text

6
58-37-4
Controlled Substance Modifications
2025 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Jennifer Dailey-Provost
Senate Sponsor: Kirk A. Cullimore
LONG TITLE
General Description:
This bill amends provisions related to the Controlled Substances Act.
Highlighted Provisions:
This bill:
classifies amanita muscaria as a controlled substance.
Money Appropriated in this Bill:
None
Other Special Clauses:
None
Utah Code Sections Affected:
AMENDS:
58-37-4
, as last amended by Laws of Utah 2024, Chapter 298
Be it enacted by the Legislature of the state of Utah:
Section 1, Section 
58-37-4
 is amended to read:
58-37-4. Schedules of controlled substances -- Schedules I through V -- Findings 
required -- Specific substances included in schedules.
(1)
There are established five schedules of controlled substances known as Schedules I, II, 
III, IV, and V which consist of substances listed in this section.
(2)
Schedules I, II, III, IV, and V consist of the following drugs or other substances by the 
official name, common or usual name, chemical name, or brand name designated:
(a)
Schedule I:
(i)
Unless specifically excepted or unless listed in another schedule, any of the 
following opiates, including their isomers, esters, ethers, salts, and salts of 
isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and 
salts is possible within the specific chemical designation:
(A)
Acetyl-alpha-methylfentanyl 
(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
(B)
Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
(C)
Acetylmethadol;
(D)
Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide);
(E)
Allylprodine;
(F)
Alphacetylmethadol, except levo-alphacetylmethadol also known as 
levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
(G)
Alphameprodine;
(H)
Alphamethadol;
(I)
Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] 
propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
(J)
Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4- 
piperidinyl]-N-phenylpropanamide);
(K)
Benzylpiperazine;
(L)
Benzethidine;
(M)
Betacetylmethadol;
(N)
Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4- 
piperidinyl]-N-phenylpropanamide);
(O)
Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2- 
phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
(P)
Betameprodine;
(Q)
Betamethadol;
(R)
Betaprodine;
(S)
Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide);
(T)
Clonitazene;
(U)
Cyclopropyl fentanyl 
(N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
(V)
Dextromoramide;
(W)
Diampromide;
(X)
Diethylthiambutene;
(Y)
Difenoxin;
(Z)
Dimenoxadol;
(AA)
Dimepheptanol;
(BB)
Dimethylthiambutene;
(CC)
Dioxaphetyl butyrate;
(DD)
Dipipanone;
(EE)
Ethylmethylthiambutene;
(FF)
Etizolam 
(1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4-diazepine);
(GG)
Etonitazene;
(HH)
Etoxeridine;
(II)
Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] 
furan-2-carboxamide);
(JJ)
Furethidine;
(KK)
Hydroxypethidine;
(LL)
Ketobemidone;
(MM)
Levomoramide;
(NN)
Levophenacylmorphan;
(OO)
Methoxyacetyl fentanyl 
(2-Methoxy-N-(1-phenylethylpiperidinyl-4-yl)-N-acetamide);
(PP)
Morpheridine;
(QQ)
MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
(RR)
Noracymethadol;
(SS)
Norlevorphanol;
(TT)
Normethadone;
(UU)
Norpipanone;
(VV)
Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl] 
propanamide);
(WW)
Para-fluoroisobutyryl fentanyl 
(N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
(XX)
PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
(YY)
Phenadoxone;
(ZZ)
Phenampromide;
(AAA)
Phenomorphan;
(BBB)
Phenoperidine;
(CCC)
Piritramide;
(DDD)
Proheptazine;
(EEE)
Properidine;
(FFF)
Propiram;
(GGG)
Racemoramide;
(HHH)
Tetrahydrofuran fentanyl 
(N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);
(III)
Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
(JJJ)
Tilidine;
(KKK)
Trimeperidine;
(LLL)
3-methylfentanyl, including the optical and geometric isomers 
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide);
(MMM)
3-methylthiofentanyl 
(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
(NNN)
3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also 
known as U-47700; and
(OOO)
4-cyano CUMYL-BUTINACA.
(ii)
Unless specifically excepted or unless listed in another schedule, any of the 
following opium derivatives, their salts, isomers, and salts of isomers when the 
existence of the salts, isomers, and salts of isomers is possible within the specific 
chemical designation:
(A)
Acetorphine;
(B)
Acetyldihydrocodeine;
(C)
Benzylmorphine;
(D)
Codeine methylbromide;
(E)
Codeine-N-Oxide;
(F)
Cyprenorphine;
(G)
Desomorphine;
(H)
Dihydromorphine;
(I)
Drotebanol;
(J)
Etorphine (except hydrochloride salt);
(K)
Heroin;
(L)
Hydromorphinol;
(M)
Methyldesorphine;
(N)
Methylhydromorphine;
(O)
Morphine methylbromide;
(P)
Morphine methylsulfonate;
(Q)
Morphine-N-Oxide;
(R)
Myrophine;
(S)
Nicocodeine;
(T)
Nicomorphine;
(U)
Normorphine;
(V)
Pholcodine; and
(W)
Thebacon.
(iii)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of the following 
hallucinogenic substances, or which contains any of their salts, isomers, and salts 
of isomers when the existence of the salts, isomers, and salts of isomers is possible 
within the specific chemical designation; as used in this Subsection (2)(a)(iii) 
only, "isomer" includes the optical, position, and geometric isomers:
(A)
Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; 
-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; 
-ET; and AET;
(B)
4-bromo-2,5-dimethoxy-amphetamine, some trade or other names: 
4-bromo-2,5-dimethoxy-
-methylphenethylamine; 4-bromo-2,5-DMA;
(C)
4-bromo-2,5-dimethoxyphenethylamine, some trade or other names: 
2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 
2C-B, Nexus;
(D)
2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy-
-methylphenethylamine; 2,5-DMA;
(E)
2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
(F)
4-methoxyamphetamine, some trade or other names: 4-methoxy-
-methylphenethylamine; paramethoxyamphetamine, PMA;
(G)
5-methoxy-3,4-methylenedioxyamphetamine;
(H)
4-methyl-2,5-dimethoxy-amphetamine, some trade and other names: 
4-methyl-2,5-dimethoxy-
-methylphenethylamine; "DOM"; and "STP";
(I)
3,4-methylenedioxy amphetamine;
(J)
3,4-methylenedioxymethamphetamine (MDMA);
(K)
3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl- 
alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, 
MDEA;
(L)
N-hydroxy-3,4-methylenedioxyamphetamine, also known as 
N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy 
MDA;
(M)
3,4,5-trimethoxy amphetamine;
(N)
Bufotenine, some trade and other names: 3-(
-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; 
N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
(O)
Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
(P)
Dimethyltryptamine, some trade or other names: DMT;
(Q)
Ibogaine, some trade and other names: 7-Ethyl-6,6
,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] 
azepino [5,4-b] indole; Tabernanthe iboga;
(R)
Lysergic acid diethylamide;
(S)
Marijuana;
(T)
Mescaline;
(U)
Parahexyl, some trade or other names: 
3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; 
Synhexyl;
(V)
Peyote, meaning all parts of the plant presently classified botanically as 
Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any 
extract from any part of such plant, and every compound, manufacture, salts, 
derivative, mixture, or preparation of such plant, its seeds or extracts 
(Interprets 21 USC 812(c), Schedule I(c) (12));
(W)
N-ethyl-3-piperidyl benzilate;
(X)
N-methyl-3-piperidyl benzilate;
(Y)
Psilocybin;
(Z)
Psilocyn;
(AA)
Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis 
(cannabis plant), except for marijuana as defined in Subsection 
58-37-2
(1)(aa)(i)(E), as well as synthetic equivalents of the substances contained in the 
cannabis plant, or in the resinous extractives of Cannabis, sp. and/or synthetic 
substances, derivatives, and their isomers with similar chemical structure and 
pharmacological activity to those substances contained in the plant, such as the 
following: 
1 cis or trans tetrahydrocannabinol, and their optical isomers 
6 cis or 
trans tetrahydrocannabinol, and their optical isomers 
3,4 cis or trans 
tetrahydrocannabinol, and its optical isomers, and since nomenclature of these 
substances is not internationally standardized, compounds of these structures, 
regardless of numerical designation of atomic positions covered;
(BB)
Ethylamine analog of phencyclidine, some trade or other names: 
N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine, 
N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
(CC)
Pyrrolidine analog of phencyclidine, some trade or other names: 
1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
(DD)
Thiophene analog of phencyclidine, some trade or other names: 
1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, 
TPCP, TCP; and
(EE)
1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
(iv)
Unless specifically excepted or unless listed in another schedule, any material 
compound, mixture, or preparation which contains any quantity of the following 
substances having a depressant effect on the central nervous system, including its 
salts, isomers, and salts of isomers when the existence of the salts, isomers, and 
salts of isomers is possible within the specific chemical designation:
(A)
Mecloqualone; and
(B)
Methaqualone.
(v)
Any material, compound, mixture, or preparation containing any quantity of the 
following substances having a stimulant effect on the central nervous system, 
including their salts, isomers, and salts of isomers:
(A)
Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 
or 4,5-dihydro-5-phenyl-2-oxazolamine;
(B)
Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone, 
alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
(C)
Fenethylline;
(D)
Methcathinone, some other names: 2-(methylamino)-propiophenone; 
alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; 
alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; 
N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432, 
its salts, optical isomers, and salts of optical isomers;
(E)
(
)cis-4-methylaminorex ((
)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
(F)
N-ethylamphetamine; and
(G)
N,N-dimethylamphetamine, also known as 
N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
(vi)
Any material, compound, mixture, or preparation which contains any quantity of 
the following substances, including their optical isomers, salts, and salts of 
isomers, subject to temporary emergency scheduling:
(A)
N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
(B)
N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
(vii)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of gamma 
hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and 
salts of isomers.
(b)
Schedule II:
(i)
Unless specifically excepted or unless listed in another schedule, any of the 
following substances whether produced directly or indirectly by extraction from 
substances of vegetable origin, or independently by means of chemical synthesis, 
or by a combination of extraction and chemical synthesis:
(A)
Opium and opiate, and any salt, compound, derivative, or preparation of 
opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, 
naloxone, and naltrexone, and their respective salts, but including:
(I)
Raw opium;
(II)
Opium extracts;
(III)
Opium fluid;
(IV)
Powdered opium;
(V)
Granulated opium;
(VI)
Tincture of opium;
(VII)
Codeine;
(VIII)
Ethylmorphine;
(IX)
Etorphine hydrochloride;
(X)
Hydrocodone;
(XI)
Hydromorphone;
(XII)
Metopon;
(XIII)
Morphine;
(XIV)
Oxycodone;
(XV)
Oxymorphone; and
(XVI)
Thebaine;
(B)
Any salt, compound, derivative, or preparation which is chemically equivalent 
or identical with any of the substances referred to in Subsection (2)(b)(i)(A), 
except that these substances may not include the isoquinoline alkaloids of 
opium;
(C)
Opium poppy and poppy straw;
(D)
Coca leaves and any salt, compound, derivative, or preparation of coca leaves, 
and any salt, compound, derivative, or preparation which is chemically 
equivalent or identical with any of these substances, and includes cocaine and 
ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives, 
whether derived from the coca plant or synthetically produced, except the 
substances may not include decocainized coca leaves or extraction of coca 
leaves, which extractions do not contain cocaine or ecgonine; and
(E)
Concentrate of poppy straw, which means the crude extract of poppy straw in 
either liquid, solid, or powder form which contains the phenanthrene alkaloids 
of the opium poppy.
(ii)
Unless specifically excepted or unless listed in another schedule, any of the 
following opiates, including their isomers, esters, ethers, salts, and salts of 
isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and 
salts is possible within the specific chemical designation, except dextrorphan and 
levopropoxyphene:
(A)
Alfentanil;
(B)
Alphaprodine;
(C)
Anileridine;
(D)
Bezitramide;
(E)
Bulk dextropropoxyphene (nondosage forms);
(F)
Carfentanil;
(G)
Dihydrocodeine;
(H)
Diphenoxylate;
(I)
Fentanyl;
(J)
Isomethadone;
(K)
Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol, 
levomethadyl acetate, or LAAM;
(L)
Levomethorphan;
(M)
Levorphanol;
(N)
Metazocine;
(O)
Methadone;
(P)
Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
(Q)
Moramide-Intermediate, 2-methyl-3-morpholino-1, 
1-diphenylpropane-carboxylic acid;
(R)
Pethidine (meperidine);
(S)
Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
(T)
Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
(U)
Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
(V)
Phenazocine;
(W)
Piminodine;
(X)
Racemethorphan;
(Y)
Racemorphan;
(Z)
Remifentanil; and
(AA)
Sufentanil.
(iii)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of the following 
substances having a stimulant effect on the central nervous system:
(A)
Amphetamine, its salts, optical isomers, and salts of its optical isomers;
(B)
Methamphetamine, its salts, isomers, and salts of its isomers;
(C)
Phenmetrazine and its salts; and
(D)
Methylphenidate.
(iv)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of the following 
substances having a depressant effect on the central nervous system, including its 
salts, isomers, and salts of isomers when the existence of the salts, isomers, and 
salts of isomers is possible within the specific chemical designation:
(A)
Amobarbital;
(B)
Glutethimide;
(C)
Pentobarbital;
(D)
Phencyclidine;
(E)
Phencyclidine immediate precursors: 1-phenylcyclohexylamine and 
1-piperidinocyclohexanecarbonitrile (PCC); and
(F)
Secobarbital.
(v)
(A)
Unless specifically excepted or unless listed in another schedule, any 
material, compound, mixture, or preparation which contains any quantity of 
Phenylacetone.
(B)
Some of these substances may be known by trade or other names: 
phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
(vi)
Nabilone, another name for nabilone: (
)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6, 
6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
(vii)
A drug product or preparation that contains any component of marijuana, 
including tetrahydrocannabinol, and is approved by the United States Food and 
Drug Administration and scheduled by the Drug Enforcement Administration in 
Schedule II of the federal Controlled Substances Act, Title II, P.L. 91-513.
(c)
Schedule III:
(i)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of the following 
substances having a stimulant effect on the central nervous system, including its 
salts, isomers whether optical, position, or geometric, and salts of the isomers 
when the existence of the salts, isomers, and salts of isomers is possible within the 
specific chemical designation:
(A)
Those compounds, mixtures, or preparations in dosage unit form containing 
any stimulant substances listed in Schedule II, which compounds, mixtures, or 
preparations were listed on August 25, 1971, as excepted compounds under 
Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other 
drug of the quantitive composition shown in that list for those drugs or which 
is the same except that it contains a lesser quantity of controlled substances;
(B)
Benzphetamine;
(C)
Chlorphentermine;
(D)
Clortermine; and
(E)
Phendimetrazine.
(ii)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of the following 
substances having a depressant effect on the central nervous system:
(A)
Any compound, mixture, or preparation containing amobarbital, secobarbital, 
pentobarbital, or any salt of any of them, and one or more other active 
medicinal ingredients which are not listed in any schedule;
(B)
Any suppository dosage form containing amobarbital, secobarbital, or 
pentobarbital, or any salt of any of these drugs which is approved by the
 United 
States
 Food and Drug Administration for marketing only as a suppository;
(C)
Any substance which contains any quantity of a derivative of barbituric acid 
or any salt of any of them;
(D)
Chlorhexadol;
(E)
Buprenorphine;
(F)
Any drug product containing gamma hydroxybutyric acid, including its salts, 
isomers, and salts of isomers, for which an application is approved under the 
federal Food, Drug, and Cosmetic Act, Section 505;
(G)
Ketamine, its salts, isomers, and salts of isomers, some other names for 
ketamine: 
 -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
(H)
Lysergic acid;
(I)
Lysergic acid amide;
(J)
Methyprylon;
(K)
Sulfondiethylmethane;
(L)
Sulfonethylmethane;
(M)
Sulfonmethane; and
(N)
Tiletamine and zolazepam or any of their salts, some trade or other names for 
a tiletamine-zolazepam combination product: Telazol, some trade or other 
names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade 
or other names for zolazepam: 
4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] 
[1,4]-diazepin-7(1H)-one, flupyrazapon.
(iii)
Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in 
a U.S. Food and Drug Administration approved drug product, some other names 
for dronabinol: 
(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, 
or (-)-delta-9-(trans)-tetrahydrocannabinol.
(iv)
Nalorphine.
(v)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation containing limited quantities of any of the 
following narcotic drugs, or their salts calculated as the free anhydrous base or 
alkaloid:
(A)
Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 
milligrams per dosage unit, with an equal or greater quantity of an isoquinoline 
alkaloid of opium;
(B)
Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 
milligrams per dosage unit, with one or more active non-narcotic ingredients in 
recognized therapeutic amounts;
(C)
Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not 
more than 15 milligrams per dosage unit, with a fourfold or greater quantity of 
an isoquinoline alkaloid of opium;
(D)
Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not 
more than 15 milligrams per dosage unit, with one or more active, non-narcotic 
ingredients in recognized therapeutic amounts;
(E)
Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more 
than 90 milligrams per dosage unit, with one or more active non-narcotic 
ingredients in recognized therapeutic amounts;
(F)
Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more 
than 15 milligrams per dosage unit, with one or more active, non-narcotic 
ingredients in recognized therapeutic amounts;
(G)
Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, 
or not more than 25 milligrams per dosage unit, with one or more active, 
non-narcotic ingredients in recognized therapeutic amounts; and
(H)
Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams 
with one or more active, non-narcotic ingredients in recognized therapeutic 
amounts.
(vi)
Unless specifically excepted or unless listed in another schedule, anabolic 
steroids including any of the following or any isomer, ester, salt, or derivative of 
the following that promotes muscle growth:
(A)
Boldenone;
(B)
Chlorotestosterone (4-chlortestosterone);
(C)
Clostebol;
(D)
Dehydrochlormethyltestosterone;
(E)
Dihydrotestosterone (4-dihydrotestosterone);
(F)
Drostanolone;
(G)
Ethylestrenol;
(H)
Fluoxymesterone;
(I)
Formebulone (formebolone);
(J)
Mesterolone;
(K)
Methandienone;
(L)
Methandranone;
(M)
Methandriol;
(N)
Methandrostenolone;
(O)
Methenolone;
(P)
Methyltestosterone;
(Q)
Mibolerone;
(R)
Nandrolone;
(S)
Norethandrolone;
(T)
Oxandrolone;
(U)
Oxymesterone;
(V)
Oxymetholone;
(W)
Stanolone;
(X)
Stanozolol;
(Y)
Testolactone;
(Z)
Testosterone; and
(AA)
Trenbolone.
(vii)
Anabolic steroids expressly intended for administration through implants to 
cattle or other nonhuman species, and approved by the Secretary of Health and 
Human Services for use, may not be classified as a controlled substance.
(viii)
A drug product or preparation that contains any component of marijuana, 
including tetrahydrocannabinol, and is approved by the United States Food and 
Drug Administration and scheduled by the Drug Enforcement Administration in 
Schedule III of the federal Controlled Substances Act, Title II, P.L. 91-513.
(ix)
Nabiximols.
(x)
Amanita Muscaria.
(d)
Schedule IV:
(i)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation containing not more than 1 milligram of 
difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or 
any salts of any of them.
(ii)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of the following 
substances, including its salts, isomers, and salts of isomers when the existence of 
the salts, isomers, and salts of isomers is possible within the specific chemical 
designation:
(A)
Alprazolam;
(B)
Barbital;
(C)
Bromazepam;
(D)
Butorphanol;
(E)
Camazepam;
(F)
Carisoprodol;
(G)
Chloral betaine;
(H)
Chloral hydrate;
(I)
Chlordiazepoxide;
(J)
Clobazam;
(K)
Clonazepam;
(L)
Clorazepate;
(M)
Clotiazepam;
(N)
Cloxazolam;
(O)
Delorazepam;
(P)
Diazepam;
(Q)
Dichloralphenazone;
(R)
Estazolam;
(S)
Ethchlorvynol;
(T)
Ethinamate;
(U)
Ethyl loflazepate;
(V)
Fludiazepam;
(W)
Flunitrazepam;
(X)
Flurazepam;
(Y)
Halazepam;
(Z)
Haloxazolam;
(AA)
Ketazolam;
(BB)
Loprazolam;
(CC)
Lorazepam;
(DD)
Lormetazepam;
(EE)
Mebutamate;
(FF)
Medazepam;
(GG)
Meprobamate;
(HH)
Methohexital;
(II)
Methylphenobarbital (mephobarbital);
(JJ)
Midazolam;
(KK)
Nimetazepam;
(LL)
Nitrazepam;
(MM)
Nordiazepam;
(NN)
Oxazepam;
(OO)
Oxazolam;
(PP)
Paraldehyde;
(QQ)
Pentazocine;
(RR)
Petrichloral;
(SS)
Phenobarbital;
(TT)
Pinazepam;
(UU)
Prazepam;
(VV)
Quazepam;
(WW)
Temazepam;
(XX)
Tetrazepam;
(YY)
Tramadol;
(ZZ)
Triazolam;
(AAA)
Zaleplon; and
(BBB)
Zolpidem.
(iii)
Any material, compound, mixture, or preparation of fenfluramine which contains 
any quantity of the following substances, including its salts, isomers whether 
optical, position, or geometric, and salts of the isomers when the existence of the 
salts, isomers, and salts of isomers is possible.
(iv)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of the following 
substances having a stimulant effect on the central nervous system, including its 
salts, isomers whether optical, position, or geometric isomers, and salts of the 
isomers when the existence of the salts, isomers, and salts of isomers is possible 
within the specific chemical designation:
(A)
Cathine ((+)-norpseudoephedrine);
(B)
Diethylpropion;
(C)
Fencamfamine;
(D)
Fenproprex;
(E)
Mazindol;
(F)
Mefenorex;
(G)
Modafinil;
(H)
Pemoline, including organometallic complexes and chelates thereof;
(I)
Phentermine;
(J)
Pipradrol;
(K)
Sibutramine; and
(L)
SPA ((-)-1-dimethylamino-1,2-diphenylethane).
(v)
Unless specifically excepted or unless listed in another schedule, any material, 
compound, mixture, or preparation which contains any quantity of 
dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 
2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
(vi)
A drug product or preparation that contains any component of marijuana and is 
approved by the United States Food and Drug Administration and scheduled by 
the Drug Enforcement Administration in Schedule IV of the federal Controlled 
Substances Act, Title II, P.L. 91-513.
(e)
Schedule V:
(i)
Any compound, mixture, or preparation containing any of the following limited 
quantities of narcotic drugs, or their salts calculated as the free anhydrous base or 
alkaloid, which includes one or more non-narcotic active medicinal ingredients in 
sufficient proportion to confer upon the compound, mixture, or preparation 
valuable medicinal qualities other than those possessed by the narcotic drug alone:
(A)
not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
(B)
not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 
grams;
(C)
not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 
grams;
(D)
not more than 2.5 milligrams of diphenoxylate and not less than 25 
micrograms of atropine sulfate per dosage unit;
(E)
not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
(F)
not more than 0.5 milligram of difenoxin and not less than 25 micrograms of 
atropine sulfate per dosage unit; and
(G)
unless specifically exempted or excluded or unless listed in another schedule, 
any material, compound, mixture, or preparation which contains Pyrovalerone 
having a stimulant effect on the central nervous system, including its salts, 
isomers, and salts of isomers.
(ii)
A drug product or preparation that contains any component of marijuana, 
including cannabidiol, and is approved by the United States Food and Drug 
Administration and scheduled by the Drug Enforcement Administration in 
Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513. 
(iii)
Gabapentin.
Section 2. 
Effective Date.
This bill takes effect on 
May 7, 2025
.
2-13-25 9:46 AM